Abbott Laboratories (ABT) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Abbott Laboratories’s revenue went from $20.9B in fiscal 2016 to $44.3B in fiscal 2025, growth of about 8.7% a year.
Net income in fiscal 2025 was $6.5B, a net margin of 14.7%; the best year in this period was 2024 with $13.4B.
Over the twelve months to September 30, 2026, revenue was $48.2B and net income $4.7B.
Free cash flow was $7.4B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 18% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.2B | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B | $34.6B | $31.9B | $30.6B | $27.4B | $20.9B |
| Gross profit | $27.5B | $25.0B | $23.2B | $22.1B | $24.5B | $24.5B | $19.6B | $18.7B | $17.9B | $15.0B | $11.8B |
| Operating income | $6.6B | $8.1B | $6.8B | $6.5B | $8.4B | $8.4B | $5.4B | $4.5B | $3.6B | $1.6B | $3.0B |
| Net income | $4.7B | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B | $4.5B | $3.7B | $2.4B | $477M | $1.4B |
| EPS (diluted) | $2.69 | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 | $2.06 | $1.33 | $0.27 | $0.94 |
| R&D | $3.3B | $2.9B | $2.8B | $2.7B | $2.9B | $2.7B | $2.4B | $2.4B | $2.3B | $2.3B | $1.4B |
| Revenue growth | — | +5.7% | +4.6% | −8.1% | +1.3% | +24.5% | +8.5% | +4.3% | +11.6% | +31.4% | +2.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $8.9B | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B | $7.9B | $6.1B | $6.3B | $5.6B | $3.2B |
| Capital spending | -$2.1B | -$2.2B | -$2.2B | -$2.2B | -$1.8B | -$1.9B | -$2.2B | -$1.6B | -$1.4B | -$1.1B | -$1.1B |
| Free cash flow | $6.8B | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B | $5.7B | $4.5B | $4.9B | $4.4B | $2.1B |
| Dividends paid | $4.3B | $4.1B | $3.8B | $3.6B | $3.3B | $3.2B | $2.6B | $2.3B | $2.0B | $1.8B | $1.5B |
| Buybacks | $1.5B | $893M | $1.3B | $1.2B | $3.8B | $2.3B | $403M | $718M | $238M | $117M | $522M |
| Stock-based pay | $735M | $664M | $673M | $644M | $685M | $640M | $546M | $519M | $477M | $406M | $310M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $8.9B | $8.0B | $7.3B | $10.2B | $10.2B | $7.1B | $4.1B | $4.1B | $9.6B | $18.8B |
| Debt | — | $14.1B | $15.3B | $15.9B | $17.9B | $19.3B | $19.7B | $18.9B | $19.4B | $27.7B | $20.7B |
| Equity | — | $52.1B | $47.7B | $38.6B | $36.7B | $35.8B | $32.8B | $31.1B | $30.5B | $30.9B | $20.5B |
| Total assets | — | $86.7B | $81.4B | $73.2B | $74.4B | $75.2B | $72.5B | $67.9B | $67.2B | $76.2B | $52.7B |
| Shares (diluted) | 1.74B | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 56.9% | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% | 56.6% | 58.5% | 58.5% | 54.7% | 56.4% |
| Operating margin | 13.8% | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% | 15.5% | 14.2% | 11.9% | 5.7% | 14.5% |
| Net margin | 9.7% | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% |
| FCF margin | 14.0% | 16.7% | 15.1% | 12.6% | 17.9% | 20.1% | 16.5% | 14.1% | 16.0% | 16.2% | 10.0% |
| ROIC | — | 9.4% | 8.6% | 10.2% | 12.8% | 13.2% | 9.2% | 8.2% | 5.9% | 2.1% | 5.5% |
| ROE | — | 12.5% | 28.1% | 14.8% | 18.9% | 19.8% | 13.7% | 11.9% | 7.8% | 1.5% | 6.8% |
Frequently asked questions
What is Abbott Laboratories’s annual revenue?
$44.3B in fiscal 2025 and $48.2B over the twelve months to September 30, 2026.
How much profit does Abbott Laboratories make?
Net income was $6.5B in fiscal 2025 (net margin 14.7%).
Is Abbott Laboratories’s revenue growing?
Yes: revenue rose 5.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.